...
首页> 外文期刊>Cost Effectiveness Resource Allocation >Cost-effective interventions for breast cancer, cervical cancer, and colorectal cancer: new results from WHO-CHOICE
【24h】

Cost-effective interventions for breast cancer, cervical cancer, and colorectal cancer: new results from WHO-CHOICE

机译:乳腺癌,宫颈癌和结肠直肠癌的经济有效干预:由世卫组织选择的新结果

获取原文
           

摘要

Following the adoption of the Global Action Plan for the Prevention and Control of NCDs 2013-2020, an update to the Appendix 3 of the action plan was requested by Member States in 2016, endorsed by the Seventieth World Health Assembly in May 2017 and provides a list of recommended NCD interventions. The main contribution of this paper is to present results of analyses identifying how decision makers can achieve maximum health gain using the cancer interventions listed in the Appendix 3. We also present methods used to calculate new WHO-CHOICE cost-effectiveness results for breast cancer, cervical cancer, and colorectal cancer in Southeast Asia and eastern sub-Saharan Africa. We used "Generalized Cost-Effectiveness Analysis" for our analysis which uses a hypothetical null reference case, where the impacts of all current interventions are removed, in order to identify the optimal package of interventions. All health system costs, regardless of payer, were included. Health outcomes are reported as the gain in healthy life years due to a specific intervention scenario and were estimated using a deterministic state-transition cohort simulation (Markov model). Vaccination against human papillomavirus (two doses) for 9-13-year-old girls (in eastern sub-Saharan Africa) and HPV vaccination combined with prevention of cervical cancer by screening of women aged 30-49?years through visual inspection with acetic acid linked with timely treatment of pre-cancerous lesions (in Southeast Asia) were found to be the most cost effective interventions. For breast cancer, in both regions the treatment of breast cancer, stages I and II, with surgery?±?systemic therapy, at 95% coverage, was found to be the most cost-effective intervention. For colorectal cancer, treatment of colorectal cancer, stages I and II, with surgery?±?chemotherapy and radiotherapy, at 95% coverage, was found to be the most cost-effective intervention. The results demonstrate that cancer prevention and control interventions are cost-effective and can be implemented through a step-wise approach to achieve maximum health benefits. As the global community moves toward universal health coverage, this analysis can support decision makers in identifying a core package of cancer services, ensuring treatment and palliative care for all.
机译:在通过全球行动计划的预防和控制NCDS 2013-2020的情况下,2016年会员国提交了会员国对行动计划附录3的更新,由2017年5月的第七届世界卫生大会赞同并提供了一个List的推荐NCD干预措施。本文的主要贡献是展示分析结果,确定决策者如何使用附录3中列出的癌症干预措施来实现最大的健康收益。我们还提出了用于计算乳腺癌的新选择成本效益结果的方法,宫颈癌,东南亚和东部撒哈拉以南非洲癌症癌症。我们使用“广义成本效益分析”进行分析,它使用假设的空参考情况,其中所有当前干预的影响被删除,以便识别最佳干预措施。无论付款人都包括所有健康系统成本。由于特定的干预情景,恢复卫生成果作为健康生活年的收益,并使用确定性状态转换队列仿真估计(马尔可夫模型)。针对人乳头瘤病毒(两剂量)疫苗接种9-13岁的女孩(东部撒哈拉以南非洲)和HPV疫苗接种,通过筛选30-49岁的女性通过乙酸的目视检查筛选妇女筛选被发现与及时治疗癌前病变(在东南亚)被认为是最具成本效益的干预措施。对于乳腺癌,在两个地区,治疗乳腺癌,阶段I和II,手术?±?系统疗法,95%的覆盖率,被发现是最具成本效益的干预。对于结直肠癌,治疗结直肠癌,阶段I和II,手术?±α?化疗和放疗,95%的覆盖率,发现是最具成本效益的干预。结果表明,癌症预防和控制干预措施是具有成本效益,可以通过迈出的方法来实现最大的健康益处。随着全球社会迁移普遍健康覆盖,该分析可以支持决策者确定癌症服务的核心包,确保所有人的治疗和姑息治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号